Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
191. |
ECCT/13/07/04 | Advanced Kapsosis Sarcoma Chemotherapy Regimens A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya 1. WRP/KEMRI - Kericho (Kericho county) 2. AMPATH - MOI University Teaching Hospital Eldoret CRS (Uasin Gishu county) |
07-08-2012 |
View |
192. |
ECCT/25/08/06 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women |
Principal Investigator(s) 1. Irene Wambui Inwani Site(s) in Kenya 1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county) 2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county) 3. Kargeno Research & Policy Hub (Kisumu county) 4. KEMRI-CCR-PHRD, Thika site (Kiambu county) |
15-12-2025 |
View |
193. |
ECCT/24/03/06 | PHOENIx MDR-TB) Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) |
Principal Investigator(s) 1. Dr Lucy Chepkurui Koech KOECH Site(s) in Kenya 1. Kenya medical Research Institute/ Walter Reed Project (Kericho county) 2. Moi university clinic research Centre (Uasin Gishu county) |
21-05-2024 |
View |
194. |
ECCT/17/06/01 | MF/PM Phase III An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
Principal Investigator(s) 1. Jane Mbui Site(s) in Kenya 1. Kimalel Health Centre (Baringo county) 2. Kacheliba sub-county hospital (West Pokot county) |
04-10-2017 |
View |
195. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
10-06-2019 |
View |
196. |
ECCT/22/03/01 | The \"NOVATION-1\" Trial A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 |
Principal Investigator(s) 1. Dr John Kinuthia Site(s) in Kenya 1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. KEMRI Kericho (Kericho county) 4. KEMRI Siaya (Kisumu county) 5. Kenyatta National Hospital (Nairobi City county) |
27-05-2022 |
View |
197. |
ECCT/13/08/06 | Management of myocardial injury After NoncArdiac surgGEry (MANAGE) Trial |
Principal Investigator(s) 1. GERALD OCHIENG\' YONGA 2. LEONARD MZEE NGUNGA Site(s) in Kenya Aga Khan University Hospital, Nairobi |
30-11-2012 |
View |
198. |
ECCT/23/10/08 | VALUE Placebo Film Study Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal Films (MATRIX-002) |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
17-01-2024 |
View |
199. |
ECCT/24/02/09 | pionERA This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
04-08-2024 |
View |
200. |
ECCT/24/09/01 | L9LS-PD Single-use antimalarial monoclonal antibodies for post-discharge malaria prevention in children with severe anaemia or severe malaria in Kenya: A multi-centre, parallel-group, two-arm randomised placebo-controlled non-inferiority trial (L9LS-pd) |
Principal Investigator(s) 1. Mary Iwaret Otiti Site(s) in Kenya 1. Homa Bay County Teaching and Referral Hospital (Homa Bay county) 2. Siaya County Referral Hospital (Siaya county) |
16-03-2025 |
View |